Name: 글로벌 시장 동향
SKU: PH7793
Availability: InStock

보고서 요약(국문)

개요
전 세계 표층점상각막염 시장은 2022년 XX백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 XX%의 성장률을 보이며 2030년에는 XX백만 달러에 이를 것으로 예상됩니다.
표층점상각막염은 각막 표면의 작은 세포 집단이 괴사하여 발생하는 안구 질환입니다. 일반적으로 세균이나 바이러스 감염, 눈에 강한 화학 물질이 유입되는 경우, 콘택트렌즈를 장기간 착용하는 경우 등이 원인이 될 수 있습니다.
표층점상각막염이 있는 경우, 눈은 보통 아프고 눈물이 나며, 밝은 빛에 민감하고, 충혈되며, 시야가 약간 흐려질 수 있습니다. 또한, 눈에 작열감, 이물감 또는 이물질이 들어간 듯한 느낌이 나타날 수 있습니다.

시장 동향: 성장 동인 및 제약 요인
연구 개발 활동 증가
의료 수요 증가, 기술 발전, 제약 생산 증가, 전염병 유병률 증가 등의 요인이 시장 성장을 견인할 것으로 예상됩니다. 개발도상국 및 저개발국의 열악한 위생 환경으로 인해 질병 발생률이 증가하고 있습니다.
표면점상각막염 치료를 위한 신약 개발 연구 개발 활동 증가는 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다. 치료 선택지가 늘어나면 환자들에게 도움이 되고, 이는 결과적으로 시장 성장을 촉진합니다.
제약 요인
엄격한 승인 규제
엄격한 규제, 높은 연구 개발 비용, 특허 만료, 치료에 대한 보험 적용 정책 부족은 시장 성장을 저해할 것으로 예상됩니다.
세분화 분석
전 세계 표면점상각막염 시장은 약물, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.

국소 나타마이신(5%) 부문은 시장 점유율의 38.4%를 차지했습니다.
나타마이신은 질병 치료에 효과적이기 때문에 시장에서 상당한 비중을 차지할 것으로 예상됩니다. 국소 나타마이신은 표재성 진균증의 1차 치료제입니다. 나타마이신은 테트라엔 폴리엔 계열 약물로, 진균성 각막염 치료에 가장 중요한 약물로 여겨져 왔습니다. 표재성 점상 각막염의 경우, 눈은 일반적으로 통증이 있고, 눈물이 나며, 밝은 빛에 민감하고, 충혈되며, 시야가 약간 흐려질 수 있습니다.
나타마이신은 사상균 감염에 대한 주요 선택 약물로 여겨지지만, 높은 분자량과 낮은 용해도로 인해 각막 침투력이 떨어지며, 주로 표재성 각막염에 효과적입니다. 따라서 이러한 요인들이 해당 부문을 시장에서 지배적인 위치로 유지할 것으로 예상됩니다.

지리적 분석
북미는 전 세계 표층점상각막염 시장에서 상당한 비중을 차지할 것으로 예상됩니다.
북미 지역은 질병 유병률 증가, 질병 확산에 대한 인식 제고를 위한 보건 캠페인 활성화, 그리고 질병 예방 약물을 출시하는 주요 업체들의 존재로 인해 가장 큰 시장 점유율을 기록했습니다.
이 지역의 콘택트렌즈 사용자 증가 또한 표층점상각막염 유병률 증가에 기여할 것으로 예상됩니다. 표층점상각막염은 콘택트렌즈 착용과 관련된 가장 흔한 문제이며, 안구건조증으로 인해 발생할 수 있습니다. 일반적으로 각막 하반부에 형광염색으로 염색된 작은 점들이 흩어져 있는 형태로 나타납니다. 따라서 이러한 요인들이 북미 지역 시장 성장을 견인하고 있습니다.
코로나19 영향 분석
코로나19는 표층점상각막염 시장에 부정적인 영향을 미쳤습니다. 기업들의 관심 증가와 코로나19 백신 및 치료제 수요 증가가 시장에 악영향을 미쳤습니다.

시장 세분화
의약품별
● 국소 나타마이신(5%)
● 암포테리신 B
o 바시트라신
o 겐타마이신
● 보리코나졸
● 단기 작용 산동제
o 사이클로펜톨레이트 1% 점안액
● 로테맥스
투여 경로별
● 경구
● 국소
● 정맥 주사
유통 채널별
● 병원 약국
● 소매 약국
● 온라인 약국
지역별
● 북미
o 미국
o 캐나다
o 멕시코
● 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
● 남미
o 브라질
o 아르헨티나
o 기타 남미
● 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
● 중동 및 아프리카
경쟁 환경
상당한 시장 점유율을 차지하는 주요 기업으로는 Harrow Inc., Thermo Fisher Scientific Inc., Matinas 등이 있습니다. BioPharma Hldgs, Glenmark Pharmaceuticals Limited, Cayman Chemical Company, Dr. Reddy’s Laboratories Ltd., Gilead Sciences Inc., Xellia ApS, Merck KGaA, Pfizer Inc. 등이 포함됩니다.

보고서 구매 이유:

● 장비 유형, 치료 유형, 최종 사용자 및 지역별 전 세계 표재성 점상 각막염 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악합니다.

● 트렌드 분석 및 공동 개발을 통해 사업 기회를 식별합니다.

● 모든 세그먼트를 포함한 표재성 점상 각막염 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

● 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

● 모든 주요 기업의 핵심 제품을 포함하는 제품 맵핑 Excel 파일을 제공합니다.

전 세계 표재성 점상 각막염 시장 보고서는 약 61개의 표, 68개의 그림, 183페이지로 구성됩니다.

2023년 목표 고객층
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Superficial Punctate Keratitis Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.
Superficial punctate keratitis is an eye disorder caused by the death of small groups of cells on the surface of the cornea. It is usually caused by infection by bacteria, viruses, strong spillage of chemicals in the eye, prolonged usage of contact lenses, and others.
In superficial punctate keratitis, the eyes are usually painful, watery, sensitive to bright light, and bloodshot, and vision may be slightly blurred. Also, there will be a burning, gritty feeling or a feeling as if a foreign object is trapped in the eye.
Market Dynamics: Drivers & Restraints
Increase in research and developmental activities
Factors such as an increase in the demand for healthcare, technological advancements, increasing pharma production, and the rising prevalence of contagious diseases are expected to drive the market growth. The incidence of the disease is rising due to the poor sanitary conditions in the developing and underdeveloped nations.
The increase in the research and developmental activities in developing new drugs for treating superficial punctate keratitis is expected to drive the market growth in the forecast period. The increase in the number of drug options helps the individuals suffering from the disease which in return increases the market growth.
Restraint
Stringent regulations associated with the approvals
The stringent regulations, high costs of research and development, and patent expirations. The lack of reimbursement policies for the treatment is expected to hinder market growth.
Segment Analysis
The global superficial punctate keratitis market is segmented based on drugs, route of administration, distribution channel and region.
Topical Natamycin (5%) segment accounted for 38.4% of the market share
Natamycin is expected to hold a significant position in the market share due to its efficiency in treating the disease. Topical natamycin is the first-line therapy for superficial mycosis. Natamycin is a tetraene polyene that has been regarded as the most important agent in the management of fungal keratitis. In superficial punctate keratitis, the eyes are usually painful, watery, sensitive to bright light, and bloodshot, and vision may be slightly blurred.
Natamycin is considered a primary choice for filamentous fungal infections but is characterized by poor corneal penetration due to its high molecular weight and poor solubility and is mostly effective in cases of superficial keratitis. Thus, the above factors are expected to hold the segment in the dominant position.
Geographical Analysis
North America is expected to hold a significant position in the global superficial punctate keratitis market share
North American region accounted for the largest market share due to the increased prevalence of the disease, and increased health campaigns in the region to bring awareness among individuals regarding the spread of the disease and the presence of major players in introducing the medications that prevent the disease.
The increase in the number of individuals using contact lenses in the region is also expected to increase the prevalence of the disease. This is the most common problem associated with contact lens wearing and may occur as a result of dry eye. It is then usually seen in the lower half of the cornea as little scattered fluorescein staining dots. Thus, the above factors are driving the market growth in the region.
COVID-19 Impact Analysis
COVID-19 has impacted the superficial punctate keratitis market negatively. The shift in the company's interest and increased demand for COVID-19 vaccines and medicines has impacted the market negatively.
Market Segmentation
By Drugs
● Topical Natamycin (5%)
● Amphotericin B
o Bacitracin
o Gentamicin
● Voriconazole
● Short-acting Cycloplegic Drug
o Cyclopentolate 1% Drop
● LOTEMAX
By Route of Administration
● Oral
● Topical
● Intravenous
By Distribution Channel
● Hospital Pharmacies
● Retail Pharmacies
● Online Pharmacies
By Region
● North America
o U.S.
o Canada
o Mexico
● Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
● South America
o Brazil
o Argentina
o Rest of South America
● Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
● Middle East and Africa
Competitive Landscape
The leading companies with a significant market share include Harrow Inc., Thermo Fisher Scientific Inc., Matinas BioPharma Hldgs, Glenmark Pharmaceuticals Limited, Cayman Chemical Company, Dr. Reddy’s Laboratories Ltd., Gilead Sciences Inc., Xellia ApS, Merck KGaA, Pfizer Inc. among others.
Why Purchase the Report?
● To visualize the global superficial punctate keratitis market segmentation based on equipment type, treatment type, end-users and region as well as understand key commercial assets and players.
● Identify commercial opportunities by analyzing trends and co-development.
● Excel data sheet with numerous data points of superficial punctate keratitis market-level with all segments.
● PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
● Product mapping available as excel consisting of key products of all the major players.
The global superficial punctate keratitis market report would provide approximately 61 tables, 68 figures, and 183 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drugs
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increase in research and developmental activities
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Stringent regulations associated with the approvals
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Equipment Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
7.1.2. Market Attractiveness Index, By Drugs
7.2. Topical Natamycin (5%) *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Amphotericin B
7.3.1. Bacitracin
7.3.2. Gentamicin
7.4. Voriconazole
7.5. Short-acting Cycloplegic Drug
7.5.1. Cyclopentolate 1% Drop
7.6. LOTEMAX
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Topical
8.4. Intravenous
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.2. Market Attractiveness Index, By Distribution Channel
9.3. Hospitals *
9.3.1. Introduction
9.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.4. Specialty Clinics
9.5. Ambulatory Surgical Centers
9.6. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.5.1. China
10.5.5.2. India
10.5.5.3. Japan
10.5.5.4. Australia
10.5.5.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Harrow Inc *
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Thermo Fisher Scientific Inc
12.3. Matinas BioPharma Hldgs
12.4. Glenmark Pharmaceuticals Limited
12.5. Cayman Chemical Company
12.6. Dr. Reddy’s Laboratories Ltd.
12.7. Gilead Sciences Inc.
12.8. Xellia ApS
12.9. Merck KGaA
12.10. Pfizer Inc.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Harrow Inc, 4.	Key Developments, Thermo Fisher Scientific Inc, Matinas BioPharma Hldgs, Glenmark Pharmaceuticals Limited, Cayman Chemical Company, Dr. Reddy’s Laboratories Ltd., Gilead Sciences Inc., Xellia ApS, Merck KGaA, Pfizer Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Superficial Punctate Keratitis Market Value, By Drugs, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Superficial Punctate Keratitis Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Superficial Punctate Keratitis Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Superficial Punctate Keratitis Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Superficial Punctate Keratitis Market Value, By Drugs, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Superficial Punctate Keratitis Market Value, By Drugs, 2022-2031 (US$ Million)

Table 7 Global Superficial Punctate Keratitis Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Superficial Punctate Keratitis Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 9 Global Superficial Punctate Keratitis Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Superficial Punctate Keratitis Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 11 Global Superficial Punctate Keratitis Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Superficial Punctate Keratitis Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Superficial Punctate Keratitis Market Value, By Drugs, 2022-2031 (US$ Million)

Table 14 North America Superficial Punctate Keratitis Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 15 North America Superficial Punctate Keratitis Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 16 North America Superficial Punctate Keratitis Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Superficial Punctate Keratitis Market Value, By Drugs, 2022-2031 (US$ Million)

Table 18 South America Superficial Punctate Keratitis Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 19 South America Superficial Punctate Keratitis Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 20 South America Superficial Punctate Keratitis Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Superficial Punctate Keratitis Market Value, By Drugs, 2022-2031 (US$ Million)

Table 22 Europe Superficial Punctate Keratitis Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 23 Europe Superficial Punctate Keratitis Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 24 Europe Superficial Punctate Keratitis Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Superficial Punctate Keratitis Market Value, By Drugs, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Superficial Punctate Keratitis Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Superficial Punctate Keratitis Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Superficial Punctate Keratitis Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East & Africa Superficial Punctate Keratitis Market Value, By Drugs, 2022-2031 (US$ Million)

Table 30 Middle East & Africa Superficial Punctate Keratitis Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 31 Middle East & Africa Superficial Punctate Keratitis Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 32 Harrow Inc.: Overview

Table 33 Harrow Inc.: Product Portfolio

Table 34 Harrow Inc.: Key Developments

Table 35 Thermo Fisher Scientific Inc: Overview

Table 36 Thermo Fisher Scientific Inc: Product Portfolio

Table 37 Thermo Fisher Scientific Inc: Key Developments

Table 38 Matinas BioPharma Hldgs: Overview

Table 39 Matinas BioPharma Hldgs: Product Portfolio

Table 40 Matinas BioPharma Hldgs: Key Developments

Table 41 Glenmark Pharmaceuticals Limited: Overview

Table 42 Glenmark Pharmaceuticals Limited: Product Portfolio

Table 43 Glenmark Pharmaceuticals Limited: Key Developments

Table 44 Cayman Chemical Company: Overview

Table 45 Cayman Chemical Company: Product Portfolio

Table 46 Cayman Chemical Company: Key Developments

Table 47 Dr. Reddy’s Laboratories Ltd.: Overview

Table 48 Dr. Reddy’s Laboratories Ltd.: Product Portfolio

Table 49 Dr. Reddy’s Laboratories Ltd.: Key Developments

Table 50 Gilead Sciences Inc.: Overview

Table 51 Gilead Sciences Inc.: Product Portfolio

Table 52 Gilead Sciences Inc.: Key Developments

Table 53 Xellia ApS: Overview

Table 54 Xellia ApS: Product Portfolio

Table 55 Xellia ApS: Key Developments

Table 56 Merck KGaA: Overview

Table 57 Merck KGaA: Product Portfolio

Table 58 Merck KGaA: Key Developments

Table 59 Pfizer Inc.: Overview

Table 60 Pfizer Inc.: Product Portfolio

Table 61 Pfizer Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Superficial Punctate Keratitis Market Value, 2022-2031 (US$ Million)

Figure 2 Global Superficial Punctate Keratitis Market Share, By Drugs, 2022 & 2031 (%)

Figure 3 Global Superficial Punctate Keratitis Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 4 Global Superficial Punctate Keratitis Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 5 Global Superficial Punctate Keratitis Market Share, By Region, 2022 & 2031 (%)

Figure 6 Global Superficial Punctate Keratitis Market Y-o-Y Growth, By Drugs, 2022-2031 (%)

Figure 7 Topical Natamycin (5%) Superficial Punctate Keratitis Market Value, 2022-2031 (US$ Million)

Figure 8 Amphotericin B Superficial Punctate Keratitis Market Value, 2022-2031 (US$ Million)

Figure 9 Voriconazole Superficial Punctate Keratitis Market Value, 2022-2031 (US$ Million)

Figure 10 Short-acting Cycloplegic Drug Superficial Punctate Keratitis Market Value, 2022-2031 (US$ Million)

Figure 11 LOTEMAX Superficial Punctate Keratitis Market Value, 2022-2031 (US$ Million)

Figure 12 Global Superficial Punctate Keratitis Market Y-o-Y Growth, By Route of Administration, 2022-2031 (%)

Figure 13 Oral Route of Administration in Global Superficial Punctate Keratitis Market Value, 2022-2031 (US$ Million)

Figure 14 Topical Route of Administration in Global Superficial Punctate Keratitis Market Value, 2022-2031 (US$ Million)

Figure 15 Intravenous Route of Administration in Global Superficial Punctate Keratitis Market Value, 2022-2031 (US$ Million)

Figure 16 Global Superficial Punctate Keratitis Market Y-o-Y Growth, By Distribution Channel, 2022-2031 (%)

Figure 17 Hospital pharmacies Distribution Channel in Global Superficial Punctate Keratitis Market Value, 2022-2031 (US$ Million)

Figure 18 Retail pharmacies Distribution Channel in Global Superficial Punctate Keratitis Market Value, 2022-2031 (US$ Million)

Figure 19 Online pharmacies Distribution Channel in Global Superficial Punctate Keratitis Market Value, 2022-2031 (US$ Million)

Figure 20 Global Superficial Punctate Keratitis Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 21 North America Superficial Punctate Keratitis Market Value, 2022-2031 (US$ Million)

Figure 22 Asia-Pacific Superficial Punctate Keratitis Market Value, 2022-2031 (US$ Million)

Figure 23 Europe Superficial Punctate Keratitis Market Value, 2022-2031 (US$ Million)

Figure 24 South America Superficial Punctate Keratitis Market Value, 2022-2031 (US$ Million)

Figure 25 Middle East and Africa Superficial Punctate Keratitis Market Value, 2022-2031 (US$ Million)

Figure 26 North America Superficial Punctate Keratitis Market Value, 2022-2031 (US$ Million)

Figure 27 North America Superficial Punctate Keratitis Market Share, By Drugs, 2022 & 2031 (%)

Figure 28 North America Superficial Punctate Keratitis Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 29 North America Superficial Punctate Keratitis Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 30 North America Superficial Punctate Keratitis Market Share, By Country, 2022 & 2031 (%)

Figure 31 South America Superficial Punctate Keratitis Market Value, 2022-2031 (US$ Million)

Figure 32 South America Superficial Punctate Keratitis Market Share, By Drugs, 2022 & 2031 (%)

Figure 33 South America Superficial Punctate Keratitis Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 34 South America Superficial Punctate Keratitis Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 35 South America Superficial Punctate Keratitis Market Share, By Country, 2022 & 2031 (%)

Figure 36 Europe Superficial Punctate Keratitis Market Value, 2022-2031 (US$ Million)

Figure 37 Europe Superficial Punctate Keratitis Market Share, By Drugs, 2022 & 2031 (%)

Figure 38 Europe Superficial Punctate Keratitis Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 39 Europe Superficial Punctate Keratitis Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 40 Europe Superficial Punctate Keratitis Market Share, By Country, 2022 & 2031 (%)

Figure 41 Asia-Pacific Superficial Punctate Keratitis Market Value, 2022-2031 (US$ Million)

Figure 42 Asia-Pacific Superficial Punctate Keratitis Market Share, By Drugs, 2022 & 2031 (%)

Figure 43 Asia-Pacific Superficial Punctate Keratitis Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 44 Asia-Pacific Superficial Punctate Keratitis Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 45 Asia-Pacific Superficial Punctate Keratitis Market Share, By Country, 2022 & 2031 (%)

Figure 46 Middle East & Africa Superficial Punctate Keratitis Market Value, 2022-2031 (US$ Million)

Figure 47 Middle East & Africa Superficial Punctate Keratitis Market Share, By Drugs, 2022 & 2031 (%)

Figure 48 Middle East & Africa Superficial Punctate Keratitis Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 49 Middle East & Africa Superficial Punctate Keratitis Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 50 Harrow Inc.: Financials

Figure 51 Thermo Fisher Scientific Inc: Financials

Figure 52 Matinas BioPharma Hldgs: Financials

Figure 53 Glenmark Pharmaceuticals Limited: Financials

Figure 54 Cayman Chemical Company: Financials

Figure 55 Dr. Reddy’s Laboratories Ltd.: Financials

Figure 56 Gilead Sciences Inc.: Financials

Figure 57 Xellia ApS: Financials

Figure 58 Merck KGaA: Financials

Figure 59 Pfizer Inc.: Financials

세계 표재성 점상 각막염 시장 – 2023-2030

Global Superficial Punctate Keratitis Market - 2023-2030